Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Organ-on-a-Chip, Tissue-on-a-Chip & Organoids Europe 2020

Robert Vries's Biography



Robert Vries, CEO, Hubrecht Organoid Technology (HUB)

Robert received his PhD in Biochemistry form the Leiden University Medical Center on a molecular study of oncogenic transformation. He subsequently moved to Stanford University (USA) to do his Post Doc studying neural stem cells. Upon his return to the Netherlands he continued the study of adult stem cells in the group of Prof Hans Clevers at the Hubrecht Institute in The Netherlands.
In the group of Hans Clevers he was part of the team that developed the breakthrough technology that allowed the expansion of adult stem cells. The so-called Organoid Technology became the basis of the company ‘Hubrecht Organoid Technology’ (HUB) of which he is currently the CEO.

Robert Vries Image

Novel Organoid Models to Develop Drug Treatment Strategies

Wednesday, 9 September 2020 at 10:00

Add to Calendar ▼2020-09-09 10:00:002020-09-09 11:00:00Europe/LondonNovel Organoid Models to Develop Drug Treatment StrategiesOrgan-on-a-Chip, Tissue-on-a-Chip and Organoids Europe 2020 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com

Organoids such as IPSC derived brain organoids (Lancaster et al Nature 2013) or our adults epithelial stem cell derived organoids (Sato et al., Nature 2009, 2011) are proving to be a major breakthrough in preclinical models. The new patient like models are fundamental change in the way drug discovery and development can be performed. The development of the HUB Organoids started in the lab of Hans Clevers with the discovery of the identity of adult stem cells in human epithelial tissues such as intestine and liver (Barker et al., Nature 2007; Huch et al., Nature 2013). With the identification of these stem cells, we were able to develop a culture system that allowed for the virtually unlimited, genetically and phenotypically stable expansion of the epithelial cells from animals including humans, both from healthy and diseased tissue (Sato et al., Nature 2009, 2011; Gastroenterology 2011; Huch et al., Nature 2013, Cell 2015; Boj et al., Cell 2015).

We have now generated HUB organoid models from most epithelial organs. Recently, we and others have demonstrated that the in vitro response of organoids correlates with the clinical outcome of the patient from which the organoid was derived (Dekkers et al., Sci Trans Med 2016; Sachs et al., Cell 2018; Vlachogiannis et al., Science 2018). In addition, we have developed a coculture system using HUB Organoids and the immune system to study this interaction and drugs that target the role of the immune system in cancer and other diseases.

We have recently developed new models to study intestinal and lung barrier function and transport of the epithelium of these organs. These experiments show how organoids can be used to study mechanism that underly barrier function disruption in IBD or COPD. Furthermore, we have developed new models to study the interaction between immune system and epithelium. The combination of the new coculture models and assay development to study the epithelium allows us new insights into disease mechanisms and drug treatment strategies.


Add to Calendar ▼2020-09-09 00:00:002020-09-10 00:00:00Europe/LondonOrgan-on-a-Chip, Tissue-on-a-Chip and Organoids Europe 2020Organ-on-a-Chip, Tissue-on-a-Chip and Organoids Europe 2020 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com